SIMBADOL is indicated for the control of postoperative pain associated with surgical procedures in cats. Simbadol is the first and only buprenorphine FDA approved for cats. It has demonstrated safety and efficacy in more than 200 cats treated with SIMBADOL. It provides up to 3 once-daily subcutaneous doses for a total of 72 hours of pain control.
The dosage of SIMBADOL is 0.24 mg/kg (0.11 mg/lb) administered subcutaneously once daily, for up to 3 days. Administer the first dose approximately 1 hour prior to surgery.
Do not dispense SIMBADOL for administration at home by the pet owner
(see Human Safety).
CONTRAINDICATIONS: SIMBADOL is contraindicated in cats with known hypersensitivity to buprenorphine hydrochloride or any of the components of SIMBADOL, or known intolerance to opioids.
INDICATONSIMBADOL is indicated for the control of postoperative pain associated with surgical procedures in cats.
IMPORTANT SAFETY INFORMATIONWARNINGS, PRECAUTIONS and CONTRAINDICATIONS: Due to serious human safety and abuse concerns, including physical or psychological dependence, life-threatening respiratory depression and additive CNS depressant effects, read the full prescribing information before using this drug, including the complete Boxed Warning. Not for use in humans. Hospital staff should be trained in the handling of potent opioids and should avoid accidental exposure. For subcutaneous (SQ) injectable use in cats. Opioid excitation has been observed up to 8 hours after anesthetic recovery. Use with caution in cats with impaired hepatic function. SIMBADOL has not been evaluated in breeding, pregnant or lactating cats, in cats younger than 4 months of age or moribund cats. Do not use in cats with known hypersensitivity to buprenorphine hydrochloride or any of the components of SIMBADOL, or known intolerance to opioids. See the full prescribing information including the complete Boxed Warning for human safety and adverse reactions.